Ascendis Pharma A/S
ASND
#1374
Rank
$16.415 B
Marketcap
Denmark
Country
$250.25
Share price
-1.70%
Change (1 day)
20.92%
Change (1 year)
Categories
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a…
Key Metrics
Trailing P/E
18.52
Forward P/E
24.92
EPS (TTM)
$12.91
Forward EPS
$11.07
Price / Book
9.53
EV / EBITDA
58.2x
Beta
—
Dividend Yield
—
Return on Equity
118.78%
Return on Assets
9.58%
Debt / Equity
31.33
Current Ratio
2.99
Gross Margin
91.30%
Operating Margin
64.98%
Net Profit Margin
70.84%
Free Cash Flow
$12.772M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-7.91%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$820.196M
Latest Net Income$-259,719,803
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Ascendis Pharma A/S with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ASND
No recent news available. Set FINNHUB_API_KEY to enable news.
